Showing 1411-1420 of 1492 results for "".
- Acanya Announces College Scholarship Programhttps://practicaldermatology.com/news/20121010-acanya_announces_college_scholarship_program/2459711/Sponsored by Valeant Dermatology, the I Acanya Succeed Scholarship program was created to help students who have had acne and have actively tried to address it. The scholarship will award a total of up to $48,000 each to three US citize
- Dr. Siegel Discusses Sedation Without Drugshttps://practicaldermatology.com/news/Dr-Siegel-Discusses-Sedation-Without-Drugs/2471217/A significant portion of today’s patient population is interested in all-natural alternatives to drugs when possible, and sedation is an area where some useful options exist, according to Daniel M. Siegel, MD. “Sedation without drugs [is important] if you have new-age patients or, I guess,
- Acne Vaccine Could Be 'Revolutionary,' Dr. Stein Gold Sayshttps://practicaldermatology.com/news/Acne-Vaccine-Could-Be-Revolutionary-Dr-Stein-Gold-Says/2471165/The next major breakthrough in acne could be a “revolutionary” vaccine targeting the strain of c. Acnes bacteria that produces the Hyl-A enzyme, Linda Stein Gold, MD, said at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “It is still in early clinical trials, but I t
- Literature Review Examines Need for Better Treatment of PsO in Skin of Colorhttps://practicaldermatology.com/news/Literature-Review-Examines-Need-Better-Treatment-PsO-Skin-Color/2471097/A recent literature review on psoriasis in patients with skin of color (SOC) “invokes an important call to action by the [International Psoriasis Council],” its authors wrote I the International Journal of Dermatology. “Education on diagnosing and treating psoriasis in all populations, inc
- Lecture Updates on Abrocitinib, Povorcitinib for PNhttps://practicaldermatology.com/news/lecture-updates-abrocitinib-povorcitinib-pn/2468486/Dr. Shawn Kwatra gets goosebumps when he thinks about having two approved biologics for prurigo nodularis, (PN) he said during a session at the 44th Annual Fall Clinical Dermatology Conference. “I have to pinch myself,” Dr. Kwatra said during “Making the Connection Between Prurigo Nodulari
- Dermavant Publishes ADORING 1 & ADORING 2 Phase 3 Trial Results for Vtama Cream for ADhttps://practicaldermatology.com/news/dermavant-publishes-adoring-1-adoring-2-phase-3-trial-results-vtama-cream-ad/2463173/Dermavant Sciences announced that the data from ADORING 1 and ADORING 2 phase 3 trials of Vtama (tapinarof) cream 1% for adults and children 2 years of age and older with atopic dermatitis (AD) has been published in the Journal of the American Academy of Dermatology. Vtama cream i
- Revance's Erica Jordan Promoted to CCOhttps://practicaldermatology.com/news/revances-erica-jordan-promoted-to-coo/2462124/Erica Jordan is now Revance Therapeutics, Inc.’s Chief Commercial Officer (CCO), Aesthetics. “Given the importance of the DAXXIFY launch, I’m excited to elevate Erica to the position of Chief Commercial Officer, Aesthetics reporting directly to me. Having wo
- Sciton Adds 1064nm Wavelength to mJOULE Platformhttps://practicaldermatology.com/news/sciton-adds-1064nm-wavelength-to-mjoule-platform/2462081/Sciton Inc. is expanding their mJOULE system to include ClearV and ClearSilk to treat vascular lesions and skin discoloration. "The combination of 1064 in the ClearV and ClearSilk delivery systems with the narrowband 532+ BBL filter replaces the need for all other vascular lasers i
- Oro Health, Dermago Unveil Consumer Version of its AI-powered Dermatology Assessment and Recommendation Toolhttps://practicaldermatology.com/news/oro-health-dermago-unveil-consumer-version-of-its-ai-powered-dermatology-assessment-and-recommendation-tool/2461822/Oro Health and Dermago are unveiling the public version of DermSmart, a tool designed to classify skin types and minor skin conditions. This new AI-driven version offers patients the ability to upload pictures of their skin condition, ask questions and interact with the tool i
- Take That, Melanoma: Universal Cancer Vaccine Boosts Overall Survivalhttps://practicaldermatology.com/news/take-that-melanoma-universal-cancer-vaccine-boosts-overall-survival/2461790/Ultimovacs’ UV1 universal cancer vaccine boosted overall survival in malignant melanoma, according to a three-year update from a Phase I clinical trial. UV1 is a universal cancer vaccine designed to induce a specific T cell response against telomerase. The U.S. Food and Drug Admin